•The v0.14.4 notes describe a qualified virtual block containing a single transaction with a cap of 1.1 billion Layer 2 gas, subject to specific technical conditions.
•Generating large proofs may take 1 to 2 minutes, compared with 3 to 5 seconds for the usual small-proof path at the time the notes were published.
•A StarkWare representative said on October 15, 2026, that large proofs on Sepolia would be activated in weeks after an internal audit was completed.
•The approximate value of SEGRO’s issued and to-be-issued share capital under the offer is about $18.8 billion.
•SEGRO shareholders will receive 0.0920 new Prologis shares for each share, with an optional partial cash alternative totaling up to about £3.5 billion.
•SEGRO shareholders approved the scheme on 28 September 2026, with completion of the deal expected in the first half of 2027.
•Brent fell 21% and West Texas Intermediate 17% from the start of November through November 11.
•Middle East crude and condensate supply disruptions stood at about 3.8 million barrels per day through November 11, while Saudi and Iraqi crude output returned to pre-war levels.
•Aramco cut its December-loading Arab Light price to Asia by $2, to a $6.50 discount to the Oman/Dubai average.
•Turkish industrial output rose 2.6% year on year in September 2026.
•Industrial output increased 2.1% month on month in September 2026.
•Under the May 23, 2026, decision, eight-week growth limits were 3% for general consumer loans and car loans, 4.5% for lira-denominated loans to small and medium-sized enterprises, and 2% for lira-denominated loans to other companies.
•October gold production was 23,462 ounces, bringing total production since the first pour to 24,746 ounces through the end of the month.
•The oxide circuit processed about 880,000 tonnes in October, and the plant operated at an average of more than 90% of its nameplate capacity of 11 million tonnes a year, reaching 104% in the final week.
•The average grade of ore processed was 0.82 grams of gold per tonne, and average gold recovery was 95% in October.
•Net earnings attributable to participating shareholders were C$1,006 million in the third quarter of 2026, compared with C$703 million in the same period of 2025.
•The group’s assets under management and advisement, including strategic investments, reached C$645.6 billion at September 30, 2026.
•Adjusted net asset value per share rose 32.1% to C$113.28 at September 30, 2026.
•Axon cut its 2026 revenue growth forecast to about 30%, with expected revenue of $3.61 billion to $3.63 billion.
•The company excluded three federal Dedrone projects worth approximately $130 million from its 2026 forecast and said growth would have been about 500 basis points higher if they had remained on track.
•Third-quarter revenue rose 28% to $909 million, and net income was $57 million.
•RLI declared a special dividend of $3 per share, with an expected total of nearly $275 million.
•The regular quarterly dividend is $0.18 per share; both dividends are payable on December 7 to shareholders of record on November 30, 2026.
•Operating earnings in the third quarter of 2026 were $79.3 million, or $0.86 per share, compared with $75.8 million and $0.82 per share a year earlier.
•OptimizeRx reported results for the three months ended September 30, 2026.
•Second-quarter 2026 revenue was about $20.5 million, down 30% year over year.
•In August, the company maintained its 2026 revenue guidance at $95 million to $100 million and adjusted EBITDA guidance at $21 million to $25 million.
•Aspen shares rose 2.08% in the November 5, 2026, session, the day the additional buyback was announced.
•Aspen expected the delisting and cancellation of the repurchased shares to be completed before the end of November 2026.
•Aspen is selling the European rights and intellectual property for Ovestin for 197 million euros, in addition to inventory worth about 4 million euros.
•The Fitch downgrade of the company to BB- on November 11, 2026, could not be verified; the last documented action lowered the rating to BB on January 30, 2026.
•Net asset value was $5.61 per share on September 30, compared with $6.58 on June 30.
•Non-accrual investments rose to 3.4% at fair value and 14.2% at cost on September 30, from 1.6% and 7.4% on June 30.
